SELLAS Life Sciences
26 hedge funds and large institutions have $6.64M invested in SELLAS Life Sciences in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 7 closing their positions.
576% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $224K
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
3.87% more ownership
Funds ownership: 10.64% → 14.51% (+3.9%)
0% more funds holding
Funds holding: 26 → 26 (0)
41% less capital invested
Capital invested by funds: $11.3M → $6.64M (-$4.64M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
+$2.72M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$745K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$508K |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$293K |
| 5 |
Renaissance Technologies
New York
|
+$99.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$645K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$298K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$208K |
| 4 |
D.E. Shaw & Co
New York
|
-$148K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$106K |
SLS Hedge Fund Activity: Q2 2022 in Review
26 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q2 2022, worth a combined $6.64M — down 41% from $11.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SLS positions and 7 closed out — a net gain of 1 holder — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Empery Asset Management, opening a new position worth an estimated $2.72M. The largest seller was Ameriprise, exiting entirely with an estimated $645K sold.
- 26 institutional investors held SELLAS Life Sciences (SLS) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $6.64M of SELLAS Life Sciences stock for Q2 2022, down 41% quarter-over-quarter.
- 8 funds opened new SELLAS Life Sciences positions in Q2 2022 and 7 closed out, a net change of +1 holder.
- The largest SELLAS Life Sciences buyer in Q2 2022 was Empery Asset Management, an estimated $2.72M added.
- The largest SELLAS Life Sciences seller in Q2 2022 was Ameriprise, an estimated $645K sold.
Based on aggregated 13F filings for Q2 2022.